Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.

Walter, Eva

Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. [electronic resource] - Leukemia & lymphoma Nov 2012 - 2290-2 p. digital

Publication Type: Letter

1029-2403

10.3109/10428194.2012.682311 doi


Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived--administration & dosage
Antigens, CD20--analysis
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bendamustine Hydrochloride
Cyclophosphamide--therapeutic use
Doxorubicin--therapeutic use
Female
Humans
Lymphoma, Large B-Cell, Diffuse--drug therapy
Male
Middle Aged
Nitrogen Mustard Compounds--administration & dosage
Prednisone--therapeutic use
Retrospective Studies
Rituximab
Vincristine--therapeutic use